Adlai Nortye’s (ANL) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Adlai Nortye (NASDAQ:ANL) in a report published on Tuesday,Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock.

Several other analysts also recently weighed in on ANL. Cantor Fitzgerald assumed coverage on Adlai Nortye in a report on Monday, June 22nd. They issued an “overweight” rating for the company. Wall Street Zen upgraded Adlai Nortye from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Loop Capital set a $49.00 price objective on Adlai Nortye in a research note on Tuesday. Finally, JonesTrading assumed coverage on Adlai Nortye in a report on Thursday, May 14th. They issued a “buy” rating and a $22.00 price objective for the company. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $29.50.

Adlai Nortye Stock Performance

NASDAQ ANL opened at $15.09 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.65 and a current ratio of 9.55. Adlai Nortye has a 1 year low of $0.88 and a 1 year high of $17.25. The company has a fifty day moving average of $12.89 and a two-hundred day moving average of $11.53.

Insider Activity at Adlai Nortye

In other news, CFO Xiaofeng Ye sold 5,667 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total value of $80,754.75. Following the completion of the sale, the chief financial officer directly owned 147,757 shares of the company’s stock, valued at approximately $2,105,537.25. This represents a 3.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Hedge Funds Weigh In On Adlai Nortye

A number of hedge funds and other institutional investors have recently made changes to their positions in ANL. Seven Fleet Capital Management LP acquired a new position in Adlai Nortye in the 2nd quarter valued at about $1,302,000. Braidwell LP acquired a new stake in Adlai Nortye during the 2nd quarter worth approximately $9,145,000. Boone Capital Management LLC purchased a new position in shares of Adlai Nortye in the 2nd quarter valued at approximately $2,971,000. ADAR1 Capital Management LLC purchased a new position in shares of Adlai Nortye in the 1st quarter valued at approximately $816,000. Finally, Affinity Asset Advisors LLC acquired a new position in shares of Adlai Nortye in the first quarter valued at approximately $1,140,000. Hedge funds and other institutional investors own 35.21% of the company’s stock.

Adlai Nortye Company Profile

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.